Skip to main content
. Author manuscript; available in PMC: 2024 Mar 1.
Published in final edited form as: J Allergy Clin Immunol. 2022 Dec 17;151(3):747–755. doi: 10.1016/j.jaci.2022.11.021

FIG 1.

FIG 1.

Cumulative ranking probability plots with the surface under cumulative ranking (SUCRA) for the efficacy outcomes, including exacerbation, prebronchodilator FEV1, and ACQ. Each plot displayed the cumulative ranking probabilities of each treatment’s being the best (1), second-best (2), third best (3), fourth-best (4), or worst (5) for each efficacy outcome. The best overall treatment would be the treatment with its area under the curve closet to the entire area of the graph shaped like a rectangle which reported as SUCRA value at the bottom right corner ranged from 0 to 1. The higher SUCRA indicates the better ranking. For example, tezepelumab was best treatment in reducing exacerbations with the highest SUCRA at 0.862, while dupilumab was the best for improving FEV1 with SUCRA at 0.905, and mepolizumab ranked highest for improving ACQ with SUCRA at 0.774.